- Home
- MMLP vs XFOR Comparison
MMLP vs XFOR Comparison
Compare MMLP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMLP
- XFOR
- Stock Information
- Founded
- MMLP 2002
- XFOR 2014
- Country
- MMLP United States
- XFOR United States
- Employees
- MMLP N/A
- XFOR N/A
- Industry
- MMLP Oil Refining/Marketing
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMLP Energy
- XFOR Health Care
- Exchange
- MMLP Nasdaq
- XFOR Nasdaq
- Market Cap
- MMLP 140.8M
- XFOR 118.4M
- IPO Year
- MMLP 2002
- XFOR N/A
- Fundamental
- Price
- MMLP $3.56
- XFOR $0.51
- Analyst Decision
- MMLP
- XFOR Strong Buy
- Analyst Count
- MMLP 0
- XFOR 3
- Target Price
- MMLP N/A
- XFOR $3.50
- AVG Volume (30 Days)
- MMLP 180.9K
- XFOR 2.9M
- Earning Date
- MMLP 02-12-2025
- XFOR 11-13-2024
- Dividend Yield
- MMLP 0.56%
- XFOR N/A
- EPS Growth
- MMLP N/A
- XFOR N/A
- EPS
- MMLP 0.11
- XFOR N/A
- Revenue
- MMLP $717,396,000.00
- XFOR $1,123,000.00
- Revenue This Year
- MMLP N/A
- XFOR N/A
- Revenue Next Year
- MMLP $0.80
- XFOR $652.72
- P/E Ratio
- MMLP $33.30
- XFOR N/A
- Revenue Growth
- MMLP N/A
- XFOR N/A
- 52 Week Low
- MMLP $2.04
- XFOR $0.26
- 52 Week High
- MMLP $4.13
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- MMLP 44.82
- XFOR 42.67
- Support Level
- MMLP $3.17
- XFOR $0.43
- Resistance Level
- MMLP $3.70
- XFOR $0.89
- Average True Range (ATR)
- MMLP 0.20
- XFOR 0.09
- MACD
- MMLP 0.02
- XFOR -0.04
- Stochastic Oscillator
- MMLP 52.87
- XFOR 17.61
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.